Ino80 promotes cervical cancer tumorigenesis by activating Nanog expression
Metrics: PDF 1795 views | HTML 2121 views | ?
Jing Hu1, Jie Liu1, Aozheng Chen1, Jia Lyu1, Guihai Ai1, Qiongjing Zeng1, Yi Sun1, Chunxia Chen1, Jinbo Wang1, Jin Qiu1, Yi Wu1, Jiajing Cheng1,3, Xiujuan Shi2, Liwen Song1
1Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
2Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
3The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China
Jiajing Cheng, email: [email protected]
Xiujuan Shi, email: [email protected]
Liwen Song, email: [email protected]
Keywords: Ino80, Nanog, cervical cancer, tumorigenesis, proliferation
Received: September 02, 2015 Accepted: October 10, 2016 Published: October 14, 2016
Ino80 ATPase is an integral component of the INO80 ATP-dependent chromatin-remodeling complex, which regulates transcription, DNA repair and replication. We found that Ino80 was highly expressed in cervical cancer cell lines and tumor samples. Ino80 knockdown inhibited cervical cancer cell proliferation, induced G0/G1 phase cell cycle arrest in vitro and suppressed tumor growth in vivo. However, Ino80 knockdown did not affect cell apoptosis, migration or invasion in vitro. Ino80 overexpression promoted proliferation in the H8 immortalized cervical epithelial cell line, which has low endogenous Ino80 expression as compared to cervical cancer cell lines. Ino80 bound to the Nanog transcription start site (TSS) and enhanced its expression in cervical cancer cells. Nanog overexpression in Ino80 knockdown cell lines promoted cell proliferation. This study demonstrated for the first time that Ino80 was upregulated in cervical cancer and promoted cell proliferation and tumorigenesis. Our findings suggest that Ino80 may be a potential therapeutic target for the treatment of cervical cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.